Mylan Gets Industry Aid In $50M Tax Fight At 3rd Circ.
A generic-drug manufacturer trade group told the Third Circuit on Monday that taxing patent litigation costs related to the expedited approval process for generic drugs would undermine the purpose of the...To view the full article, register now.
Already a subscriber? Click here to view full article